Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

Br J Psychiatry. 2008 Oct;193(4):279-88. doi: 10.1192/bjp.bp.108.050088.

2.

Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.

Peluso MJ, Lewis SW, Barnes TR, Jones PB.

Br J Psychiatry. 2012 May;200(5):387-92. doi: 10.1192/bjp.bp.111.101485. Epub 2012 Mar 22.

3.

Implications of the CATIE trial on treatment: extrapyramidal symptoms.

Casey DE.

CNS Spectr. 2006 Jul;11(7 Suppl 7):25-31.

PMID:
16816797
4.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
5.

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators.

Am J Psychiatry. 2006 Dec;163(12):2080-9.

PMID:
17151158
6.
7.

Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.

Rybakowski JK, Vansteelandt K, Remlinger-Molenda A, Fleischhacker WW, Kahn RS, Peuskens J; EUFEST Study Group.

Eur Neuropsychopharmacol. 2014 Sep;24(9):1500-5. doi: 10.1016/j.euroneuro.2014.07.001. Epub 2014 Jul 21.

PMID:
25085534
8.

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.

Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR.

J Clin Psychopharmacol. 2008 Apr;28(2):203-9. doi: 10.1097/JCP.0b013e318166c4d5. Review.

9.

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA.

J Clin Psychiatry. 1998 Feb;59(2):69-75.

PMID:
9501888
10.

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.

Barnes TR, McPhillips MA.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S49-57. Review.

PMID:
9690971
11.

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA.

J Clin Psychiatry. 2011 Jan;72(1):75-80. doi: 10.4088/JCP.09m05258gre. Epub 2010 Sep 21.

12.

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Correll CU, Leucht S, Kane JM.

Am J Psychiatry. 2004 Mar;161(3):414-25. Review.

PMID:
14992963
13.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM.

J Clin Psychiatry. 1997 May;58(5):205-11. Erratum in: J Clin Psychiatry 1997 Jun;58(6):275.

PMID:
9184614
14.

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

Leucht S, Wahlbeck K, Hamann J, Kissling W.

Lancet. 2003 May 10;361(9369):1581-9. Review.

PMID:
12747876
15.
16.

Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.

Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, Lieberman J.

Schizophr Res. 2009 Aug;113(1):12-8. doi: 10.1016/j.schres.2009.06.002.

PMID:
19545976
18.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
19.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

20.

Extrapyramidal side effects are unacceptable.

Kane JM.

Eur Neuropsychopharmacol. 2001 Oct;11 Suppl 4:S397-403. Review.

PMID:
11587887

Supplemental Content

Support Center